Companies › PepGen
1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PGN-EDODM1 Oligonucleotide for myotonic dystrophy type 1 | – | Phase 2 | Myotonic Dystrophy 1 | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06667453 | PGN-EDODM1 | Phase 2 | Myotonic Dystrophy 1 | Neurology | Mar 2027 |
| NCT07220603 | PGN-EDODM1 | Phase 2 | Myotonic Dystrophy 1 | Neurology | Jan 2029 |
Cash and short-term investments of $105m on 2026-09-30; operating cash outflow about $64m a year; runway about 20 months at that burn, to May 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Satellos Bioscience Coya Therapeutics Cognition Therapeutics DiaMedica Therapeutics IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.